Discussion
NSCLC, tumor, constipation, dysgeusia, deaths, TRAEs
TUMOR, NSCLC
BPI-9016M is a novel small-molecule TKI that targets both c-MET and AXL, which inhibits tumor cell growth, migration and invasion in NSCLC. This phase Ib dose-expansion study in 38 c-MET overexpression or This study showed that 92.1% of patients had TRAEs, and 28.9% had grade ≥ 3 TRAEs. One (2.6%) patient discontinued the study treatment owing to TRAE. The most common TRAEs were elevated ALT (36.8%), elevated AST (28.9%), dysgeusia (23.7%), PPE (23.7%) and constipation (21.1%). No treatment-related deaths occurred. The phase II GEOMETRY mono-1 study evaluated capmatinib in The GEOMETRY mono-1 study showed that the ORR with capmatinib was 41% in patients with previously treated The c-MET is overexpressed in approximately 35–72% of NSCLC and was determined by IHC [Given the above-mentioned limitations, we suggest some valuable points for future studies. First, monotherapy of BPI-9016M targeting patients with c-MET overexpression (IHC staining score 3 +), In summary of this study, BPI-9016M showed manageable safety profile in c-MET overexpression or 